AmgenvsFoghorn Therapeutics

AMGN and FHTX stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$438.82

Value $237B

-1.14%
AMGN's page

FHTX

Foghorn Therapeutics Inc.

$1.78

Value $104M

-0.56%
FHTX's page

Amgen (AMGN) has a market value of $237B and Foghorn Therapeutics (FHTX) $104M. Over the last year, with dividends, AMGN moved +31.1% and FHTX -64.5%. The P/E is 25.2 for AMGN and 18.3 for FHTX. Dividend yield: AMGN 2.27%, FHTX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$237B

    FHTX$104M

    AMGN is 2,264 times FHTX

  • Revenue, 12 months

    AMGN$38.9B

    FHTX$112M

    AMGN is 347 times FHTX

  • Net income, 12 months

    AMGN$9.4B

    FHTX$9.4M

    AMGN is 997 times FHTX

  • Operating margin

    AMGN32.4%

    FHTX2.1%

    30.3 points apart

  • ROIC

    AMGN16.2%

    FHTX–

  • P/E

    AMGN25.2

    FHTX18.3

    AMGN is 1.4 times FHTX

  • Dividend yield

    AMGN2.3%

    FHTX0.0%

    2.3 points apart

  • 5-year return

    AMGN+149.2%

    FHTX-87.0%

    236.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+149.2%

FHTX-87.0%

010020020222023202420252026
Returns by period
PeriodAMGNWith dividendsFHTXWith dividends
1 year since November 18, 2025+31.1%Price +27.6%-64.5%Price -64.5%
3 years since November 17, 2023+79.5%+21.5% a yearPrice +65.3%-58.2%-25.2% a yearPrice -58.2%
5 years since November 18, 2021+149.2%+20.0% a yearPrice +115.1%-87.0%-33.5% a yearPrice -87.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenFHTXFoghorn Therapeutics

Valuation

AMGNFHTX
Valuation
Price$438.82$1.78
Market value$237B$104M
Enterprise value (EV)$277B$24M
P/E25.218.3
P/E, 5-year median23.0–
P/B16.5–
EV/EBIT22.010.2
Free cash flow yield4.1%–

Results and growth

AMGNFHTX
Results and growth
Revenue, 12 months$38.9B$112M
Net income, 12 months$9.4B$9.4M
Free cash flow, 12 months$9.6B-$84M
Earnings per share, 12 months$17.25$0.10
Revenue growth, year on year10.0%36.8%
Revenue growth a year, past+7.6%over 5 years+135.1%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNFHTX
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%2.1%
Net margin24.1%8.4%
ROIC16.2%–
ROE87.8%–

Balance sheet

AMGNFHTX
Balance sheet
Cash$13.2B$80M
Total debt$54.0B$44M
Net debt / EBITDA2.3-14.1
Interest cover4.8×–

Dividends and buybacks

AMGNFHTX
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or FHTX

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Foghorn Therapeutics?

By market value, Amgen ($237B) is about 2,264.0 times Foghorn Therapeutics ($104M), at today's prices.

How did AMGN and FHTX stock do over the last 5 years?

Since November 18, 2021, AMGN's price moved +115.1% and FHTX's -87.0%. With dividends: AMGN +149.2% (+20.0% a year), FHTX -87.0% (-33.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or FHTX?

The dividend yield at today's price is 2.27% for Amgen and none for Foghorn Therapeutics. Over the last twelve months they paid $9.94 and – per share.

What is the P/E of AMGN and FHTX?

At today's price, the P/E is 25.2 for AMGN and 18.3 for FHTX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Amgen or Foghorn Therapeutics?

Over the last twelve months, the net margin was 24.1% for Amgen and 8.4% for Foghorn Therapeutics, and the operating margin 32.4% and 2.1%. Revenue was $38.9B and $112M.

Which is the better investment, Amgen or Foghorn Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.